Effects of single dose intranasal oxytocin on social cognition in schizophrenia

Schizophrenia Research

Volumn 147, Issue 2-3, 2013, Pages 393-397

  Davis, Michael C ^a,b   Lee, Junghee ^a,b   Horan, William P ^b   Clarke, Angelika D ^a,b   McGee, Mark R ^b   Green, Michael F ^a,b   Marder, Stephen R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Clinical trial; Oxytocin; Schizophrenia; Social cognition

Indexed keywords

OXYTOCIN; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE DEFECT; DECEPTION; DRUG EFFECT; EMPATHY; FACIAL AFFECT PERCEPTION; FACIAL AFFECT RECOGNITION; HUMAN; MALE; MIRECC GLOBAL ASSESSMENT OF FUNCTIONING; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PERCEPTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SARCASM; SCHIZOPHRENIA; SCORING SYSTEM; SINGLE DRUG DOSE; SOCIAL ASPECT; SOCIAL BEHAVIOR; SOCIAL COGNITION; SOCIAL COGNITION COMPOSITE SCORE; TASK PERFORMANCE; THEORY OF MIND; VETERAN;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; COGNITION; DOUBLE-BLIND METHOD; EMPATHY; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OXYTOCIN; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR; SOCIAL PERCEPTION; THEORY OF MIND; YOUNG ADULT;

EID: 84878999878     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.04.023     Document Type: Article

References (35)

1. Ambady N., Hallahan M., Rosenthal R. On judging and being judged accurately in zero-acquaintance situations. J. Pers. Soc. Psychol. 1995, 69(3):518.
2. Andreasen N.C. Negative symptoms in schizophrenia. Definition and reliability. Arch. Gen. Psychiatry 1982, 39(7):784-788.
3. Averbeck B.B., Bobin T., Evans S., Shergill S.S. Emotion recognition and oxytocin in patients with schizophrenia. Psychol. Med. 2011, 1-8.
4. Bartz J.A., Zaki J., Bolger N., Hollander E., Ludwig N.N., Kolevzon A., Ochsner K.N. Oxytocin selectively improves empathic accuracy. Psychol. Sci. 2010, 21(10):1426-1428.
5. Born J., Lange T., Kern W., McGregor G.P., Bickel U., Fehm H.L. Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 2002, 5(6):514-516.
6. Churchland P.S., Winkielman P. Modulating social behavior with oxytocin: how does it work? What does it mean?. Horm. Behav. 2012, 61(3):392-399.
7. Derntl B., Finkelmeyer A., Toygar T.K., Hulsmann A., Schneider F., Falkenberg D.I., Habel U. Generalized deficit in all core components of empathy in schizophrenia. Schizophr. Res. 2009, 108(1-3):197-206.
8. Ditzen B., Nater U.M., Schaer M., La Marca R., Bodenmann G., Ehlert U., Heinrichs M. Sex-specific effects of intranasal oxytocin on autonomic nervous system and emotional responses to couple conflict. Soc. Cogn. Affect. Neurosci. 2012, http://scan.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=22842905 (Electronic publication ahead of print).
9. Ekman P. Subtle Expression Training Tool (SETT) & Micro Expression Training Tool (METT) 2004, Paul Ekman.
10. Feifel D., Macdonald K., Nguyen A., Cobb P., Warlan H., Galangue B., Minassian A., Becker O., Cooper J., Perry W., Lefebvre M., Gonzales J., Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 2010, 68(7):678-680.
11. Fett A.K., Viechtbauer W., Dominguez M.D., Penn D.L., van Os J., Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci. Biobehav. Rev. 2011, 35(3):573-588.
12. Goldman M., Marlow-O'Connor M., Torres I., Carter C.S. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr. Res. 2008, 98(1-3):247-255.
13. Goldman M.B., Gomes A.M., Carter C.S., Lee R. Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. Psychopharmacology 2011, 216(1):101-110.
14. Grant K.M., LeVan T.D., Wells S.M., Li M., Stoltenberg S.F., Gendelman H.E., Carlo G., Bevins R.A. Methamphetamine-associated psychosis. J. Neuroimmune Pharmacol. 2012, 7(1):113-139.
15. Gray J.A., Roth B.L. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr. Bull. 2007, 33(5):1100-1119.
16. Guastella A.J., Einfeld S.L., Gray K.M., Rinehart N.J., Tonge B.J., Lambert T.J., Hickie I.B. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol. Psychiatry 2010, 67(7):692-694.
17. Guy W. Clinical Global Impression Scale. ECDEU Assistant Manual for Psychopharmacology 1976.
18. Heinrichs M., von Dawans B., Domes G. Oxytocin, vasopressin, and human social behavior. Front. Neuroendocrinol. 2009, 30(4):548-557.
19. Horan W.P., Kern R.S., Tripp C., Hellemann G., Wynn J.K., Bell M., Marder S.R., Green M.F. Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders. J. Psychiatr. Res. 2011, 45(8):1113-1122.
20. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
21. Keri S., Kiss I., Kelemen O. Sharing secrets: oxytocin and trust in schizophrenia. Soc. Neurosci. 2009, 4(4):287-293.
22. Kosfeld M., Heinrichs M., Zak P.J., Fischbacher U., Fehr E. Oxytocin increases trust in humans. Nature 2005, 435(7042):673-676.
23. Lehman A.F., Kreyenbuhl J., Buchanan R.W., Dickerson F.B., Dixon L.B., Goldberg R., Green-Paden L.D., Tenhula W.N., Boerescu D., Tek C., Sandson N., Steinwachs D.M. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr. Bull. 2004, 30(2):193-217.
24. MacDonald E., Dadds M.R., Brennan J.L., Williams K., Levy F., Cauchi A.J. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology 2011, 36(8):1114-1126.
25. Mancuso F., Horan W.P., Kern R.S., Green M.F. Social cognition in psychosis: multidimensional structure, clinical correlates, and relationship with functional outcome. Schizophr. Res. 2011, 125(2-3):143-151.
26. McDonald S., Flanagan S., Rollins J., Kinch J. TASIT: a new clinical tool for assessing social perception after traumatic brain injury. J. Head Trauma Rehabil. 2003, 18(3):219-238.
27. Meyer-Lindenberg A., Domes G., Kirsch P., Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat. Rev. Neurosci. 2011, 12(9):524-538.
28. Modabbernia A., Rezaei F., Salehi B., Jafarinia M., Ashrafi M., Tabrizi M., Hosseini S.M., Tajdini M., Ghaleiha A., Akhondzadeh S. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs 2013, 27(1):57-65.
29. Mortimer A.M. Update on the management of symptoms in schizophrenia: focus on amisulpride. Neuropsychiatr. Dis. Treat. 2009, 5:267-277.
30. Niv N., Cohen A.N., Sullivan G., Young A.S. The MIRECC version of the Global Assessment of Functioning scale: reliability and validity. Psychiatr. Serv. 2007, 58(4):529-535.
31. Pedersen C.A., Gibson C.M., Rau S.W., Salimi K., Smedley K.L., Casey R.L., Leserman J., Jarskog L.F., Penn D.L. Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia. Schizophr. Res. 2011, 132(1):50-53.
32. Rosenthal R., Hall J.A., DiMatteo M.R., Rogers P.L., Archer D. Sensitivity to Nonverbal Communication: The PONS Test 1979, Johns Hopkins University Press Baltimore.
33. Tandon R., Keshavan M.S., Nasrallah H.A. Schizophrenia, "Just the Facts": what we know in 2008 part 1: overview. Schizophr. Res. 2008, 100(1-3):4-19.
34. van Ijzendoorn M.H., Bhandari R., van der Veen R., Grewen K.M., Bakermans-Kranenburg M.J. Elevated salivary levels of oxytocin persist more than 7h after intranasal administration. Front. Neurosci. 2012, 6:174.
35. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64(6):663-667.